- Home
- PDC vs QNCX Comparison
PDC vs QNCX Comparison
Compare PDC & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PDC | QNCX |
|---|---|---|
| Founded | 2018 | 2012 |
| Country | Japan | United States |
| Employees | 20 | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.7M | 19.9M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | PDC | QNCX |
|---|---|---|
| Price | $7.10 | $1.10 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 130.1K | ★ 1.5M |
| Earning Date | 07-01-2026 | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.88 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $0.34 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.46 | $0.08 |
| 52 Week High | $8.40 | $4.55 |
Technical Indicators
Market Signals| Indicator | PDC | QNCX |
|---|---|---|
| Relative Strength Index (RSI) | 48.62 | 50.89 |
| Support Level | $4.48 | $0.10 |
| Resistance Level | $7.90 | $1.50 |
| Average True Range (ATR) | 0.77 | 0.12 |
| MACD | -0.20 | -0.06 |
| Stochastic Oscillator | 39.31 | 55.36 |
Price Performance
Historical ComparisonAbout PDC Perpetuals.com Ltd American Depositary Shares
Earlyworks Co Ltd is a blockchain-based technology company. It builds products, delivers services, and develops solutions based on a proprietary grid ledger system to leverage blockchain technology in various business settings, including advertisement tracking, online visitor management, and sales of non-fungible tokens. The company's customers represent a diverse range of industries, such as information technology, shipping, real estate, entertainment, cosmetics, and chemical products.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. Its proprietary AIDE technology is an inventive drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells. Its Phase 3 asset, eDSP, leverages the AIDE technology to encapsulate DSP into a patient's own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, A-T.